NCT07054567: A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
- State
- Under way
- Phase
- Phase 2
- People
- 96 planned
- Started
- 21 Aug 2025
- Primary completion
- May 2027
- Arms
- BL-B01D1 + pembrolizumab ± bevacizumab
- Results
- None posted
- 8 Jul 2025: Trial registered
- 21 Aug 2025: Trial started